AbbVie has announced that the U.S. FDA has approved its ADC therapy, Pivekimab sunirine (PVEK), for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). Information indicates this is the first globally approved CD123 ADC and AbbVie's first approved ADC for hematological malignancies. BPDCN is a highly aggressive and rare hematologic malignancy with features of both leukemia and lymphoma. Patients typically present with skin lesions, and the condition often spreads to the bone marrow, central nervous system, and lymph nodes. The current standard first-line clinical approach primarily involves high-intensity chemotherapy, with some patients requiring subsequent stem cell transplantation. However, overall treatment options are limited. There is a significant unmet clinical need for both treatment-naïve patients and those with relapsed or refractory disease after chemotherapy, highlighting the urgent need for innovative targeted therapies with improved safety and efficacy. Pivekimab sunirine is an ADC targeting CD123, developed for treating hematologic malignancies. The CD123 target is highly and specifically overexpressed in BPDCN tumor cells, making it an ideal therapeutic target for this disease. The U.S. FDA granted Breakthrough Therapy designation for the BPDCN indication of this drug in October 2020. This FDA approval is primarily based on data from the global multicenter Phase I/II CADENZA clinical trial, with the primary endpoint being the composite complete response rate (CR+CRc).
Comments